Number of participants with at least 1 bleeding episode · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
Therapeutic or non‐prophylactic platelet transfusion showed no clear difference in number of participants with severe or life‐threatening bleeding up… compared with prophylactic platelet transfusion (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Quality of life ‐ not reported · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
Prophylactic platelet transfusion showed no clear difference in bleeding: Numbers of patients with at least one significant bleeding… compared with non prophylactic or therapeutic platelet transfusion (low certainty).
1 finding from 1 review
Bleeding: Numbers of patients with at least one significant bleeding event · People with a haematological disorder
It is very uncertain whether prophylactic platelet transfusion changes number of participants with a significant bleeding event compared with platelet‐poor plasma (very low certainty).
1 finding from 1 review
Mortality: secondary to bleeding · People with a haematological disorder
It is very uncertain whether prophylactic platelet transfusion changes mortality: secondary to bleeding compared with platelet‐poor plasma (very low certainty).
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · People with a haematological disorder
Prophylactic platelet transfusion showed no clear difference in bleeding: Number of days on which a significant bleeding event… compared with non prophylactic or therapeutic platelet transfusion (low certainty).
1 finding from 1 review
Mortality: secondary to bleeding · People with a haematological disorder
Prophylactic platelet transfusion showed no clear difference in mortality: Secondary to bleeding compared with non prophylactic or therapeutic platelet transfusion (low certainty).
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · People with a haematological disorder
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in numbers of participants with at least 1 clinically significant… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in number of participants with WHO Grade 3 or 4 bleeding up to 30 days… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in time to first bleeding episode (days) compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · People with a haematological disorder
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality from all causes up to 30 days from study entry compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
1 finding from 1 review